Immunocore Holdings (IMCR) Cash from Financing Activities (2021 - 2026)

Immunocore Holdings (IMCR) has reported Cash from Financing Activities for 6 consecutive years, with $656000.0 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Financing Activities fell 74.28% year-over-year to $656000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 121.13% YoY) and the FY2025 annual result came in at $12.4 million, down 96.4% from the prior year.
• Cash from Financing Activities retreated to $656000.0 in Q1 2026 per IMCR's latest filing, from $4.3 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for IMCR reached as high as $396.0 million in Q1 2024 and fell as low as -$51.5 million in Q4 2024.
• A 5-year average of $35.2 million and a median of $3.7 million in 2025 frame the typical range for Cash from Financing Activities.
• The largest YoY upside for Cash from Financing Activities was 6350.76% in 2024 against a maximum downside of 923.65% in 2024.
• Year by year, Cash from Financing Activities stood at -$1.4 million in 2022, then surged by 547.69% to $6.3 million in 2023, then sank by 923.65% to -$51.5 million in 2024, then surged by 108.32% to $4.3 million in 2025, then plunged by 84.69% to $656000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $656000.0, $4.3 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.